Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to...

Allergan Aesthetics Enters Into Option to Acquire Cypris Medical

Broadcom

Flowers Foods

General Mills

NextEra Energy

J. M. Smucker

American Tower

These hot stocks combine healthy dividends with lasting brand names, making them some of the smartest picks on the market. The post 7 Hot Stocks That Will Keep You Energized With 3%-Plus Yields appeared first on InvestorPlace.

7 Hot Stocks That Will Keep You Energized With 3%-Plus Yields

Bristol-Myers

Johnson & Johnson

Novartis

Pfizer

Sanofi

Takeda Pharmaceutical

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

The Top 7 Pharmaceutical Stocks for the Next 10 Years

Dividend Diligence On AbbVie With Seeking Alpha

How Safe Is AbbVie's Dividend?

AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies

Apple

Costco

Ford Motor Company

Procter & Gamble

Visa

Mondelez

These safe stocks to buy have a low beta, attractive valuation and healthy dividends. Get in early this year to strengthen your portfolio.

7 Safe Stocks to Buy to Start Off the Year

Abbott Labs

City Hld

Graco

Mid-America Apartment Communities

Norwood Financial

RGC Resources

Trinity Industries

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average increase of 8.4% and a median increase of 6.6%.

8 Dividend Increases To Start 2021

NORTH CHICAGO, Ill., Jan. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response...

Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease

AT&T

Toronto-Dominion Bank

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Due to gains made over the past few years and our focus on building up our lower-yielding positions, the yield on the portfolio my wife and I are building fell to just over 2% last year. One of the goals that I listed for our portfolio in 2021 was to increase the average yield of our holdings.

4 High-Yield Stocks to Ring in the New Year

AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.

AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies

NORTH CHICAGO, Ill., Jan. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive leadership team will present virtually at 3:30 p.m. Central time, including Richard A....

AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Jan. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, showing that significantly more patients treated with risankizumab (150 mg)...

Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients

Merck

These two pharmaceutical stocks can significantly boost your wealth in the long run.

Got $1,000? These 2 Top Stocks Can Make You Rich

Aptiv

Disney

Howard Hughes

Intel

Southwest Airlines

2020 has taken the market capitalizations of many strong companies to lows. That means there are some great options for cheap stocks to buy in January.

7 Cheap Stocks to Buy in January For a Quick Buck

ABBV's shares have rallied hard in recent weeks. But the market is still pricing in at least a partial failure of Humira replacements.

AbbVie's Fair Value Is At Least $147 Per Share

Citigroup

Enterprise Products Partners

MPLX

Prudential Financial

Simon Property Group

SPDR S&P 500 ETF Trust

W. P. Carey

2021 could be a year in which value stocks outperform. Income potential remains a key theme for 2021 and beyond, as interest rates remain at record lows.

Top 10 Undervalued High-Yield Income Stocks For 2021

Chevron

Exxon Mobil

Boost your retirement income with these stocks.

3 Stocks That Can Pay You More Than Social Security Benefits

The elusive conjunction of safety and growing yield is a holy grail for many investors. Seeking Alpha's quant system screens seven larger large cap biotech stocks with dividends ranging from 3.16% to 5.04%.

2 Top Picks - Safe High Dividend Biotechs For 2021

Conagra Brands

Colgate-Palmolive

CVS Health

Hershey

Kimberly-Clark

Kroger

Lowe's

Realty Income Corp

Snap-on

Southern Company

Like many conservative investors I prefer to put my fixed income into a 5 year CD ladder but this year's near 0% rates have changed my strategy. Since May I have built a portfolio of defensive dividend stocks intended to replace a 5 year CD I couldn't face rolling over at today's 1.30% rate.

I Replaced A Jumbo CD With This Eclectic Portfolio Of Value-Conscious Dividend-Paying Stocks

News for AbbVie Stock (ABBV)